HIGHLIGHTS
- who: Yiqi Li et al. from the School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China have published the research work: Icariside II Exerts Anti-Type 2 Diabetic Effect by Targeting PPAR/: Involvement of ROS/NF-B/IRS1 Signaling Pathway, in the Journal: Antioxidants 2022, 8, x FOR PEER REVIEW of /2022/
- what: The authors investigated whether ICS exerted anti-T2DM profile and further explored its possible underlying mechanism both in vivo and in vitro. db/db mice were administered ICS (10 20 40 mg·kg-1 ) for 7 weeks. This study was . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.